#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Jeffrey Kraws Email
Chief Financial Officer . Syncromune
How to contact Jeffrey Kraws
Join and see Jeffrey's contact info for free!Current Roles
Employees:
31Revenue:
$5.9MAbout
Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform therapy optimized for metastatic solid tumor cancers that aims to achieve high response rates with potentially improved survival. The company is currently developing SYNC-T, a novel and personalized in situ platform therapy that combines partial tumor oncolysis and a multi-target biologic drug. The SYNC-T combination approach is designed to target multiple mechanisms of cancer, promoting in situ immune activation while battling immunosuppression. The goal is to activate T cells, enabling the immune system to recognize and attack cancer throughout the body and defend with immune memory. The first two candidates, SV-101 and SV-102, are currently in Phase 1 trials.Syncromune Address
Fort Lauderdale, FL
United States